DNAPrint Pharmaceuticals Completes the Development of an Analytical Method That Will Be Used for the Development of (Market Wire via Yahoo! Finance)
DNAPrint Genomics, Inc. today announced that its subsidiary, DNAPrint Pharmaceuticals, Inc., has completed the development of the so-called "Western blot" method, an analytical procedure that identifies a protein according to its interaction with a specific antibody, a significant step in the development of its PT-401-based proprietary drug to treat anemia.

Cepheid's Xpert GBS(TM) Test For Group B Streptococcus Run On The GeneXpert(R) System Receives 510(k) Clearance From FDA (Medical News Today)
Cepheid (Nasdaq:CPHD), a broad-based molecular diagnostics company, today announced the510(k) clearance of its first clinical molecular diagnostic product for theUnites States market. Cepheid received 510(k) clearance from the U.S. Food& Drug Administration (FDA) to market its Xpert GBS(TM) test for Group BStreptococcus (GBS) on its GeneXpert(R) platform. [click link for full article]